Clinical Trials
8 trialsNCT00828009 2023-07-07
BLP25 Liposome Vaccine and Bevacizumab After Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery
Eastern Cooperative Oncology Group
Phase 2 Completed
NCT02049151 2017-08-23
START2
EMD Serono
Phase 3 Terminated
NCT01015443 2016-10-26
INSPIRE
Merck KGaA, Darmstadt, Germany
Phase 3 Terminated
NCT01423760 2016-10-06
Common Safety Follow-up Trial of Tecemotide (L-BLP25)
Merck KGaA, Darmstadt, Germany
Phase NA Terminated
NCT00409188 2015-11-20
START
EMD Serono
Phase 3 Completed
NCT00157209 2015-11-18
Phase 2b Randomized Controlled Study of Tecemotide (L-BLP25) for Immunotherapy of NSCLC (Non-Small Cell Lung Cancer)
Merck KGaA, Darmstadt, Germany
Phase 2 Completed
NCT00960115 2015-10-21
Study of Tecemotide (L-BLP25) in Participants With Stage III Unresectable Non-small Cell Lung Cancer (NSCLC) Following Primary Chemoradiotherapy
Merck KGaA, Darmstadt, Germany
Phase 1/2 Completed
NCT00157196 2015-08-18
Safety Study of Tecemotide (L-BLP25) in Non-Small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease
Merck KGaA, Darmstadt, Germany
Phase 2 Completed